Logo

AbbVie Acquires Mavupharma for its STING (STimulator of INterferon Genes) Modulators to Treat Cancer

Share this

AbbVie Acquires Mavupharma for its STING (STimulator of INterferon Genes) Modulators to Treat Cancer

Shots:

  • AbbVie has acquired Mavupharma to develop STING modulators and to advance Mavupharma's lead candidate MAVU-104 towards clinical study
  • The focus of the acquisition is to bolster AbbVie’s early-stage oncology portfolio with the addition of Mavupharma’s platform which involves the development of transformative therapies for cancer patients
  • MAVU-104 is an orally administered ENPP1 inhibitor allowing highly controlled enhancement of STING signaling in tumors without the need for injections

Click here to read full press release/ article | Ref: AbbVie | Image: Mavupharma


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions